CONSTRUCT COMPRISING UTR SEQUENCE THAT IMPROVES INTRACELLULAR STABILITY AND BIOSYNTHESIS OF MRNA AND USE THEREOF

Unlike DNA, mRNA has the advantage of enabling transient expression of a desired protein directly in the cytoplasm without having to enter the nucleus, and thus, attempts to use mRNA vaccines are actively underway. However, mRNA has lower structural stability than DNA, and thus has limitations in industrial application. Therefore, the present invention relates to a UTR sequence that improves the intracellular stability and biosynthesis of mRNA, and a composition for stabilizing nucleic acids, comprising the UTR sequence. The UTR sequence of the present invention has excellent effects of stabilizing nucleic acids and promoting the expression of a target protein, and thus is expected to be greatly used in the health/medical field. Contrairement à l'ADN, l'ARNm présente l'avantage de permettre l'expression transitoire d'une protéine souhaitée directement dans le cytoplasme sans devoir entrer dans le noyau, et c'est pourquoi des tentatives d'utilisation de vaccins à ARNm sont activement en cours. Cependant, l'ARNm présente une stabilité structurelle inférieure à celle de l'ADN, ce qui limite ses applications industrielles. Par conséquent, la présente invention concerne une séquence UTR améliorant la stabilité intracellulaire et la biosynthèse de l'ARNm, ainsi qu'une composition destinée à stabiliser les acides nucléiques, comprenant la séquence UTR. La séquence UTR de la présente invention présente d'excellents effets de stabilisation des acides nucléiques et de promotion de l'expression d'une protéine cible, et devrait donc être largement utilisée dans le domaine de la santé/médical. mRNA는 DNA와 다르게 핵 내로 들어갈 필요없이 세포질에서 바로 일시적으로 원하는 단백질이 발현될 수 있다는 장점이 있으므로 mRNA 백신을 이용하려는 시도가 활발하게 진행되고 있으나, mRNA는 DNA에 비해 구조적으로 안정도가 낮아 산업적으로 이용하기에 한계가 있는 실정이다. 따라서 본 발명은 mRNA의 세포 내 안정성과 생합성을 향상시키는 UTR 서열, 및 이를 포함하는 핵산 안정화용 조성물에 관한 것이다. 본 발명의 UTR서열은 핵산 안정화 및 타겟 단백질의 발현 증진 효과가 우수하므로, 보건/의료 분야에서 크게 이용될 것으로 기대된다.